Conviction: Medium
Status: Researching — RSI 27.5, price $88.80, extreme oversold, continuing selloff
Quick Snapshot
| Signal |
Reading |
| Overall |
🟢 RSI 27.5 (computed) — oversold. Price $88.80, -2.2% today, -12.9% 7D, -16.0% 30D. SMA20 ~$103.90 — price -14.5% below SMA. Capitulation-level selling. |
| Moat |
Narrow (mRNA platform, oncology pipeline) |
| Key insight |
BNTX recovered slightly from $83.89 (03/11) to $88.80 (+5.8%) but RSI remains deeply oversold at 27.5. Still -14.5% below SMA. The mRNA platform being redirected toward oncology (personalized cancer vaccines, BNT327 antibody) is the thesis. Cash-rich ($18B+). Selloff driven by COVID revenue cliff concerns and oncology pipeline uncertainty. At these levels, cash provides downside support. |
Action Matrix
| Action |
Level |
Why |
| Current |
🔍 Research |
Oversold but need to understand catalyst for selloff |
| Entry Zone |
$75 - $90 |
Current $88.80 — IN ZONE |
| Stop-Loss |
$65 (-27%) |
Below multi-year support |
| Target |
$120 (+35%) |
Recovery toward SMA levels |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| BNTX |
$88.80 |
-2.2% |
-12.9% |
-16.0% |
-6.3% |
— |
27↓ |
🟢 Oversold |
🔍 Research |
Price vs Last Deep Dive (03/11)
| Metric |
03/11 |
03/12 |
Change |
| Price |
$83.89 |
$88.80 |
+$4.91 (+5.8%) |
| RSI |
23.3 |
27.5 |
+4.2 (slight recovery) |
| SMA20 |
~$105.83 |
~$103.90 |
-$1.93 (SMA declining) |
Update from 03/11: Small bounce from $83.89 to $88.80. RSI improved from 23.3 to 27.5 but still deeply oversold. SMA continues declining toward price. The -12.9% 7D and -16.0% 30D reflect sustained selling. Cash-rich thesis intact but wait for stabilization.
Company Overview
One-Liner
BioNTech is a German biotech focused on mRNA therapeutics, best known for co-developing the Pfizer-BioNTech COVID vaccine, now pivoting to oncology.
Business Model
| Question |
Answer |
| What they sell |
mRNA vaccines (COVID), oncology pipeline (personalized cancer vaccines, BNT327) |
| Who pays |
Governments (COVID vaccines), eventually patients/insurers (oncology) |
| Revenue model |
Product sales (COVID), royalties, collaboration payments |
| How sticky |
Low for COVID (declining); potentially high for oncology if approved |
Bull Case
- RSI 27.5 — Oversold on a cash-rich biotech.
- $18B+ cash — Provides years of runway and downside floor.
- Oncology pipeline — Personalized cancer vaccines, BNT327 blockbuster potential.
- mRNA platform optionality — Infectious disease beyond COVID + oncology + rare disease.
Bear Case
- COVID revenue cliff — Revenue declining 50%+ as pandemic demand fades.
- Oncology unproven at scale — Pipeline risk; phase 3 readouts needed.
- -14.5% below SMA — No sign of stabilization yet.
- Competition from Moderna — mRNA competitor with similar pivot.
- Cash burn accelerating — R&D spend rising as revenue falls.
Thesis Killers
- Major oncology trial failure
- Cash burn rate exceeds expectations
- mRNA platform shows safety concerns
Research Log
| Date |
Update |
| 2026-03-11 |
Created. RSI 23.3 extreme oversold. $83.89. -23.3% 30D. Research. |
| 2026-03-12 |
Small bounce. $88.80 (+5.8%). RSI 27.5. Still oversold. -16.0% 30D. Research. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 23 → 27: minor bounce but still oversold |
Small relief rally, not bottom confirmation |
| -14.5% below SMA with SMA declining |
No stabilization signal yet |
| $18B+ cash vs ~$20B market cap |
Cash provides meaningful downside floor |
Open Questions
- What specifically caused the -16.0% 30D crash? (Trial data? Revenue guidance? Sector rotation?)
- What is current cash burn rate?
- What are next oncology pipeline readout dates?
- Is Moderna (MRNA) selling off similarly? (Sector-wide vs company-specific?)
- What is BNT327 status and blockbuster potential?
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.